TherapeuticsMD Reports Q2 2025 Net Income of $545K, EPS of $0.05; License Revenue Increases to $1M

Reuters

2025/08/13

TherapeuticsMD Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Income of $545K, EPS of $0.05; License Revenue Increases to $1M

TherapeuticsMD, Inc. has announced its financial results for the second quarter of 2025. The company reported a net income from continuing operations of $545,000, or $0.05 per basic and diluted common share, a turnaround from a net loss of $1.05 million, or $(0.09) per share, in the same period of 2024. License revenue, primarily driven by the Mayne License Agreement, increased significantly to $1.0 million, up from $234,000 in the second quarter of 2024. This growth is primarily due to changes in sales of licensed products. Total operating expenses decreased by 45.5% to $1.647 million, down $1.376 million from the previous year, largely due to the impairment recognized in the second quarter of 2024. As of June 30, 2025, TherapeuticsMD's cash and cash equivalents stood at $6.1 million. The company continues to explore strategic alternatives, including potential mergers, acquisitions, or other business combinations, but has not set a timetable for this exploration process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811851819) on August 12, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559629007"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559629007\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559629007?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 04:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559629007","market":"fut","top_or_hot":-1,"title":"TherapeuticsMD Reports Q2 2025 Net Income of $545K, EPS of $0.05; License Revenue Increases to $1M","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TherapeuticsMD Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Net Income of $545K, EPS of $0.05; License Revenue Increases to $1M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TherapeuticsMD, Inc. has announced its financial results for the second quarter of 2025. The company reported a net income from continuing operations of $545,000, or $0.05 per basic and diluted common share, a turnaround from a net loss of $1.05 million, or $(0.09) per share, in the same period of 2024. License revenue, primarily driven by the Mayne License Agreement, increased significantly to $1.0 million, up from $234,000 in the second quarter of 2024. This growth is primarily due to changes in sales of licensed products. Total operating expenses decreased by 45.5% to $1.647 million, down $1.376 million from the previous year, largely due to the impairment recognized in the second quarter of 2024. As of June 30, 2025, TherapeuticsMD's cash and cash equivalents stood at $6.1 million. The company continues to explore strategic alternatives, including potential mergers, acquisitions, or other business combinations, but has not set a timetable for this exploration process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TXMD\">TherapeuticsMD Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811851819) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TherapeuticsMD Reports Q2 2025 Net Income of $545K, EPS of $0.05; License Revenue Increases to $1M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTherapeuticsMD Reports Q2 2025 Net Income of $545K, EPS of $0.05; License Revenue Increases to $1M\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-13 04:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TherapeuticsMD Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Net Income of $545K, EPS of $0.05; License Revenue Increases to $1M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TherapeuticsMD, Inc. has announced its financial results for the second quarter of 2025. The company reported a net income from continuing operations of $545,000, or $0.05 per basic and diluted common share, a turnaround from a net loss of $1.05 million, or $(0.09) per share, in the same period of 2024. License revenue, primarily driven by the Mayne License Agreement, increased significantly to $1.0 million, up from $234,000 in the second quarter of 2024. This growth is primarily due to changes in sales of licensed products. Total operating expenses decreased by 45.5% to $1.647 million, down $1.376 million from the previous year, largely due to the impairment recognized in the second quarter of 2024. As of June 30, 2025, TherapeuticsMD's cash and cash equivalents stood at $6.1 million. The company continues to explore strategic alternatives, including potential mergers, acquisitions, or other business combinations, but has not set a timetable for this exploration process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TXMD\">TherapeuticsMD Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811851819) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXMD","symbol_name":"TherapeuticsMD Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL7ScYZh:1","article_id":"2559629007","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559629007","pubTimestamp":1755029325,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TherapeuticsMD, Inc. has announced its financial results for the second quarter of 2025. The company reported a net income from continuing operations of $545,000, or $0.05 per basic and diluted common share, a turnaround from a net loss of $1.05 million, or $ per share, in the same period of 2024. License revenue, primarily driven by the Mayne License Agreement, increased significantly to $1.0 million, up from $234,000 in the second quarter of 2024. This growth is primarily due to changes in sales of licensed products. Total operating expenses decreased by 45.5% to $1.647 million, down $1.376 million from the previous year, largely due to the impairment recognized in the second quarter of 2024. As of June 30, 2025, TherapeuticsMD's cash and cash equivalents stood at $6.1 million. The company continues to explore strategic alternatives, including potential mergers, acquisitions, or other business combinations, but has not set a timetable for this exploration process.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TXMD":"TherapeuticsMD Inc."},"translate_title":"TherapeuticsMD报告2025年第二季度净利润为54.5万美元，每股收益为0.05美元；许可收入增至100万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXMD":0.9},"content_text":"TherapeuticsMD Reports Q2 2025 Net Income of $545K, EPS of $0.05; License Revenue Increases to $1M\n    \n\n        TherapeuticsMD, Inc. has announced its financial results for the second quarter of 2025. The company reported a net income from continuing operations of $545,000, or $0.05 per basic and diluted common share, a turnaround from a net loss of $1.05 million, or $(0.09) per share, in the same period of 2024. License revenue, primarily driven by the Mayne License Agreement, increased significantly to $1.0 million, up from $234,000 in the second quarter of 2024. This growth is primarily due to changes in sales of licensed products. Total operating expenses decreased by 45.5% to $1.647 million, down $1.376 million from the previous year, largely due to the impairment recognized in the second quarter of 2024. As of June 30, 2025, TherapeuticsMD's cash and cash equivalents stood at $6.1 million. The company continues to explore strategic alternatives, including potential mergers, acquisitions, or other business combinations, but has not set a timetable for this exploration process.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811851819) on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}